BIIB Q4 2025 Earnings — Biogen Inc. Revenue & Financial Results | Market Cap Arena

BIIBBiogen Inc.

$28B

Q4 2025 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$2.3B-7.1% YoY

Gross Profit

$1.8B78.2% margin

Operating Income

-$57M-2.5% margin

Net Income

-$48M-2.1% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

-7.1%

Cash Flow

Operating Cash Flow

$512M

Free Cash Flow

$556M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$29.4B

Total Liabilities

$11.2B

Stockholders' Equity

$18.3B

Cash & Equivalents

$3.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.3B	$2.5B	-7.1%
Gross Profit	$1.8B	$1.9B	-4.7%
Operating Income	-$57M	$509M	-111.2%
Net Income	-$48M	$267M	-118.2%

Revenue Segments

MS Product Revenues

$917M42%

TYSABRI product

$398M18%

SPINRAZA

$356M16%

Fumarate

$293M13%

Interferon

$226M10%

Geographic Segments

Non-US

$750M100%